MedTrace Logo

RIVastigmine In Vascular cognitivE Impairment

NCT00669344 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-02-10

No results posted yet for this study

Summary

The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that patients receiving Rivastigmine would improve in executive functioning domains.

Conditions

Interventions

DRUG

Exelon (rivastigmine)

Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.

DRUG

Placebo

Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • National Neuroscience Institute

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Eng King Tan, FAMS · National Neuroscience Institute, Singapore General Hospital Campus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-04-30
Completion
2008-02-29

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00669344 on ClinicalTrials.gov